Pfizer's Centers for Therapeutic Innovation (CTI)

Gary  Pisano; James  Weber; Kait  Szydlowski

Case | HBS Case Collection | September 2014

Pfizer's Centers for Therapeutic Innovation (CTI)

by Gary Pisano, James Weber and Kait Szydlowski

Abstract

In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration with Pfizer and academic medical researchers with the purpose of developing new, innovative drug candidates for testing in patients. Project teams consisted of Pfizer scientists and academics working side-by-side to reduce the time needed to bring a therapeutic drug from the lab to a patient's bedside. This case explores the academic collaboration model developed by Pfizer. What were the strengths of and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat to the Pfizer model?

Keywords: pharmaceutical industry; drug development; academic collaboration; Research and Development; innovation; translational research; Management; Operations; Problems and Challenges; Research; Science; Technology; Strategy; Biotechnology Industry; Pharmaceutical Industry; North and Central America; Europe; Asia;

Language: English

Format: Print

25 pages

Educators Purchase

Citation:

Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.

Working Paper | 2019

Long-Term Firm Growth: An Empirical Analysis of US Manufacturers 1959-2015

Giovanni Dosi, Marco Grazzi, Daniele Moschella, Gary P. Pisano and Federico Tamagni

Firm growth is an essential feature of market economies, shaping together macroeconomic performance and the evolution of industry structures. As a po-tential indicator of organizational “ﬁtness” within a competitive environment, ﬁrm growth is also a central concern to both the practice and theory of business strategy. Despite both its theoretical and practical importance, though, growth remains a poorly understood property of ﬁrms. While previous studies have documented the highly skewed nature of ﬁrm growth rates, we know far less about the persistence of growth rates over long-periods of time. For instance, do “fast growers” tend to maintain their relative growth rates advantages over long-periods or is superior growth a transitory phenomenon? Is, as predicted by evolutionary and capability based theories of the ﬁrm, the process of ﬁrm growth path-dependent or is it more akin to a random walk? The answers to these questions are central to building a robust theory of ﬁrm growth. This paper attempts to address this gap in our empirical knowledge of ﬁrm growth using a dataset that spans 50 years, which al-lows the abandonment of the assumption, common to all incumbent studies, that the stochastic paths of all ﬁrms stem from the same generating process. These exploratory results indicate that growth rate persistence is there and my be even substantial for some ﬁrms, but it is rare. We also study the links between the micro-properties of ﬁrm growth within sectors and the patterns of aggregate growth of these same sectors. Indeed, we ﬁnd circumstantial but widespread evidence that heterogeneity across ﬁrms correlates with industry dynamism.

Citation:

Dosi, Giovanni, Marco Grazzi, Daniele Moschella, Gary P. Pisano, and Federico Tamagni. "Long-Term Firm Growth: An Empirical Analysis of US Manufacturers 1959-2015." Working Paper, May 2019. View Details

Cite View Details Read Now

Faculty & Research

Pfizer's Centers for Therapeutic Innovation (CTI)

Abstract

Citation:

About the Author

More from the Author